GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Capex-to-Operating-Cash-Flow

Abbisko Cayman (HKSE:02256) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Abbisko Cayman's Capital Expenditure for the six months ended in Dec. 2024 was HK$-2.64 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was HK$-186.13 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Abbisko Cayman Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Abbisko Cayman's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Capex-to-Operating-Cash-Flow Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.03 -

Competitive Comparison of Abbisko Cayman's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Abbisko Cayman's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbisko Cayman's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Capex-to-Operating-Cash-Flow falls into.


;
;

Abbisko Cayman Capex-to-Operating-Cash-Flow Calculation

Abbisko Cayman's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-7.897) / -13.799
=N/A

Abbisko Cayman's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-2.635) / -186.129
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbisko Cayman  (HKSE:02256) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Abbisko Cayman Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has only one business segment which is the development of medicines.
Executives
Xu Yao-chang 2101 Beneficial owner
Qiming Corporate Gp Vi, Ltd. 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines